Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteogenomic Landscape and Clinical Characterization of GH-Producing Pituitary Adenoma

ABSTRACT: Gene alteration analysis on 121 GH-producing pituitary adenomas and non-target proteomics analysis with RNA sequencing analysis on 45 non-functioning pituitary adenomas (NFPAs) and 60 growth hormone (GH)-producing pituitary adenomas were performed, and integrated these results with the clinical characteristics of acromegaly. We attempted to identify key players involved in shaping the clinical features of acromegaly, especially those related to treatment efficacy. This project revealed the importance of GNAS mutations in terms of clinical and biochemical characteristics and identified novel molecules that may be involved in the responsiveness to medical treatment.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Tomoaki Tanaka

PROVIDER: PXD036604 | JPOST Repository | Thu Nov 24 00:00:00 GMT 2022

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	GH001.raw	Raw
	GH002.raw	Raw
	GH003.raw	Raw
	GH004.raw	Raw
	GH005.raw	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Proteogenomic Landscape and Clinical Characterization of GH-producing pituitary adenomas/ somatotroph pituitary neuroendocrine tumors

Project description:The clinical characteristics of growth hormone (GH)-producing pituitary adenomas vary across patients. In this study, we aimed to integrate the genetic alterations, protein expression profiles, transcriptomes, and clinical characteristics of GH-producing pituitary adenomas to detect molecules associated with acromegaly characteristics. Targeted capture sequencing and copy number analysis of 36 genes and non-targeted proteomics analysis were performed on fresh-frozen samples from 121 sporadic GH-producing pituitary adenomas. Targeted capture sequencing revealed GNAS as the only driver gene, as previously reported. Classification by consensus clustering using both RNA sequencing and proteomics revealed many similarities between the proteome and the transcriptome. Gene ontology analysis was performed for differentially expressed proteins between wild-type and mutant GNAS samples identified by non-targeted proteomics analysis and involved in G protein–coupled receptor (GPCR) pathways. The results suggested that GNAS mutations impact endocrinological features in acromegaly through GPCR pathway induction. ATP2A2 and ARID5B correlated with the GH change rate in the octreotide loading test, and WWC3, SERINC1, and ZFAND3 correlated with the tumor volume change rate after somatostatin analog treatment. These results identified a biological connection between GNAS mutations and the clinical and biochemical characteristics of acromegaly, revealing novel molecules associated with acromegaly that may affect medical treatment efficacy.

2022-11-25 | GSE213527 | GEO

Shotgun Proteomic Analysis of ESBL and non ESBL Producing Klebsiella Pneumoniae Clinical Isolates

Project description:Shotgun Proteomic Analysis of ESBL and non ESBL Producing Klebsiella Pneumoniae Clinical Isolates

2022-02-24 | PXD011558 | Pride

Shotgun Proteomic Analysis of ESBL and non ESBL Producing Klebsiella Pneumoniae Clinical Isolates

Project description:Shotgun Proteomic Analysis of ESBL and non ESBL Producing Klebsiella Pneumoniae Clinical Isolates

2021-04-16 | PXD011693 | Pride

Pseudomonas aeruginosa clinical isolates

Project description:35 P. aeruginosa clinical strains were cultivated under standard conditions, characterized in terms of virulence and biofilm phenotype, and their metabolomes were investigated by untargeted liquid chromatography-mass spectrometry.

2022-07-12 | MSV000089869 | MassIVE

GNPS Pseudomonas aeruginosa clinical isolates

2022-07-12 | MSV000089869 | GNPS

Gene expression profiling of Chinese Hamster Ovary production cell lines

Project description:The dataset set consists of 295 microarrays from 121 individual CHO cultures producing a range of biologics including monoclonal antibodies, fusion proteins and therapeutic factors; non-producing cell lines were also included. Samples were taken from a wide range of process scales and formats that varied in terms of seeding density, temperature, medium, feed medium, culture duration and product type. Cells were sampled for gene expression analysis at various stages of the culture and bioprocess-relevant characteristics including cell density, growth rate, viability, lactate, ammonium and cell specific productivity (Qp) were determined A total of 295 microarray samples were assayed. In addition 9 continous bioprocess variables were also measured.

2011-07-27 | E-GEOD-30321 | biostudies-arrayexpress

Interval colorectal cancer in a Dutch population: Epidemiological, clinical and pathological characteristics and molecular analysis.

Project description:Interventions: None: niet WMO-plichtig onderzoek. Retrospective analysis of clinical and pathology records, and molecular analysis on resection specimen. Primary outcome(s): 1. Prevalence of interval CRCs in a Dutch population; 2. Clinical characteristics; 3. Molecular characteristics; 4. Differences with non-interval CRCs. Study Design: N/A: single arm study, N/A , unknown, Parallel

| 17347 | ecrin-mdr-crc

Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis

Project description:Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half the patient population. This study aims to identify biomarkers for early imrecoxib efficacy evaluation in OA for personalized therapy optimization. From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed proteins (DEPs) were validated using enzyme-linked immunosorbent assay (ELISA). Sixty-six patients with knee OA were included and divided into responders (n=35) and non-responders (n=31). Proteomic analysis was conducted on 15 patients from each group, and ELISA validation was performed for every patient. We found 140 DEPs between the two groups after administering imrecoxib treatment, characterized by 29 proteins showing up-regulation and 111 displaying down-regulation (p < 0.05, fold change > ±1.2). Galectin-1 (LGALS1), galectin-3 (LGALS3), and the cluster of differentiation 44 (CD44) could be utilized to evaluate the clinical response to imrecoxib in the treatment of OA after ELISA validation.This study successfully identified biomarkers for evaluating imrecoxib's clinical response in OA patients using 4D-DIA technology. These biomarkers may play a vital role in future personalized OA treatment strategies, pending further confirmation.

2024-01-19 | PXD047236 | Pride

Serum proteome of dogs with precursor-targeted immune-mediated anemia before and after splenectomy

Project description:There have been clinical reports of splenectomy as a treatment option for immune-mediated hematologic diseases in humans and dogs. We focused on the efficacy of splenectomy as a treatment for dogs with precursor-targeted immune-mediated anemia. We collected serum samples of pre and post splenectomy in these dogs to investigate the factors that might improve non-regenerative anemia after splenectomy.

2023-02-28 | PXD039913 | JPOST Repository